Punjab, April 2 -- Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record dataCollaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providersTARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 /PRNewswire/ - TriNetX(R)andRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic collaboration to support Regeneron's capabilities in drug discovery and development, as well as new initiatives to del...